Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT00346372
Recruitment Status : Recruiting
First Posted : June 29, 2006
Last Update Posted : January 4, 2018
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center

Brief Summary:
During regularly scheduled appointments, Optical Coherence Tomography (OCT) is performed on consented subjects. The OCT is a new type of camera that takes very detailed pictures inside of the eye and deeper into eye tissues. Optical Coherence Tomography imaging of intraocular tumors may lead to improved diagnosis and monitoring of tumors within the eye.

Condition or disease
Ocular Melanoma

Study Type : Observational
Estimated Enrollment : 800 participants
Observational Model: Cohort
Time Perspective: Prospective
Study Start Date : March 2004
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : January 2021

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who meet the following Eligibility Criteria

Inclusion Criteria:

  • Adults (18 years or older) with:

    • choroidal nevus greater than or equal to 3.0 mm in longest basal diameter, or greater than or equal to 1.25 mm in apical height or:
    • choroidal melanoma located in the posterior pole (4mm or less from the center of fovea or the border of the optic nerve head)

Exclusion Criteria:

  • Ocular media opacity in the tumor eye that prevents adequate functional testing or imaging and prior or concurrent retinal or choroidal disease in the tumor eye that prevents adequate functional testing or imaging

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00346372

Contact: Tara A McCannel, MD, PhD (310) 206-7484
Contact: Brangel Rangel 310 794-9962

United States, California
Jules Stein Eye Institute Recruiting
Los Angeles, California, United States, 90095
Contact: Brenda Rangel    310-794-9962   
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
Principal Investigator: Bradley R Straatsma, MD, JD Jules Stein Eye Institute, UCLA

Responsible Party: Jonsson Comprehensive Cancer Center Identifier: NCT00346372     History of Changes
Other Study ID Numbers: UCLA IRB#03-11-052
First Posted: June 29, 2006    Key Record Dates
Last Update Posted: January 4, 2018
Last Verified: January 2018

Keywords provided by Jonsson Comprehensive Cancer Center:
Ocular Melanoma
Optical Coherence Tomography
Eye Tumor
Choroidal Melanoma
Uveal Melanoma

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas